A phase 3, randomized, observer-blind, multi-center study to compare the safety and immunogenicity of one dose of Novartis meningococcal ACWY conjugate vaccine with one dose of licensed meningococcal ACWY conjugate vaccine administered to healthy children 2-10 years of age.

Trial Profile

A phase 3, randomized, observer-blind, multi-center study to compare the safety and immunogenicity of one dose of Novartis meningococcal ACWY conjugate vaccine with one dose of licensed meningococcal ACWY conjugate vaccine administered to healthy children 2-10 years of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 30 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Aug 2010 Actual initiation date changed from Feb 2008 to Mar 2008 as reported by ClinicalTrials.gov.
    • 30 Aug 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top